Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3321635 | 0.98 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| Hydrochloric Acid SCHEMBL7501282 | 0.91 | ENPP1 (0.35) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL1011889 | 0.84 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL29416616 | 0.84 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL858136 | 0.81 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL2621720 | 0.78 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL28421484 | 0.78 | MAP4K4 (0.41) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL30562904 | 0.78 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DENPP1 | |
| SCHEMBL3320604 | 0.78 | RET (0.31) | EGFRKDRFLT1FGFR1 | |
| SCHEMBL282157 | 0.78 | ENPP1 (0.44) | PDE4APDE4BPDE4CPDE4DENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513262-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| US-20050130996-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2005-06-16 | — | — | US | disclosed |
| EP-1454907-A1 | Quninazoline and pyridopyrmidine derivatives | Glaxo Group Limited (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-6727256-B1 | 4-AMINOQUINAZOLINE DERIVATIVES AS ANTICARCINOGENIC AGENTS | SMITHKLINE BEECHAM CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6713485-B2 | ANTIPROLIFERATIVE AGENTS; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION | 2004-03-30 | — | — | US | disclosed |
| CN-1134438-C | Bicyclic heteroaromatic compounds, preparation method and use thereof | �ձ���ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| CN-1292788-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 2001-04-25 | — | — | CN | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | PDE4A 4110/4885PDE4B 3445/4885PDE4C 4039/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | PDE4A 2656/4885PDE4B 2260/4885PDE4C 2036/4885 |
| US-20050130996-A1 | Heterocyclic compounds | CCNH, SDHA, CYP1A2 | PDE4A 3506/4885PDE4B 3099/4885PDE4C 3296/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PDE4A 3981/4885PDE4B 3862/4885PDE4C 3595/4885 |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ABL1, ERBB2, CDK2 | PDE4A 3670/4885PDE4B 3772/4885PDE4C 3609/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | PDE4A 783/4885PDE4B 833/4885PDE4C 1122/4885 |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | ABL1, ERBB2, SRC | PDE4A 3981/4885PDE4B 3862/4885PDE4C 3595/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PDE4A 3981/4885PDE4B 3862/4885PDE4C 3595/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PDE4A 3981/4885PDE4B 3862/4885PDE4C 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.